Nasopharyngeal Cancer Pipeline H2 2016 Market Report
PUNE, India, October 14, 2016 /PRNewswire/ --
ReportsnReports.com adds "Nasopharyngeal Cancer - Pipeline Review, H2 2016" market research report with an overview of the Nasopharyngeal Cancer's therapeutic pipeline, comprehensive information complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngeal Cancer and special features on late-stage and discontinued projects.
Nasopharyngeal Cancer pipeline therapeutics constitutes close to 39 molecules. Out of which approximately 28 molecules are developed by Companies and remaining by the Universities/Institutes. Global Markets Direct's latest report Nasopharyngeal Cancer - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Complete report on H2 2016 pipeline review of Nasopharyngeal Cancer with 40 market data tables and 15 figures, spread across 194 pages is available at http://www.reportsnreports.com/reports/703639-nasopharyngeal-cancer-pipeline-review-h2-2016.html .
Nasopharyngeal cancer is a rare type of head and neck cancer. It starts in the upper part of your throat, behind the nose. This area is called the nasopharynx. The risk factors of nasopharyngeal cancer may include Epstein-Barr virus. Symptoms of nasopharyngeal cancer may include blurry or double vision, difficulty speaking, including hoarseness, ear infections that keep coming back, face pain or numbness, headache, hearing loss, ringing in the ears. Treatment includes surgery, chemotherapy and radiation therapy. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 7, 10, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 1 and 5 molecules, respectively. Furthermore, this report also reviews of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.
Companies discussed in this Nasopharyngeal Cancer Pipeline Review, H2 2016 report include Advenchen Laboratories, LLC, Ambrx, Inc., arGEN-X BV, Atara Biotherapeutics, Inc., AVEO Pharmaceuticals, Inc., Betta Pharmaceuticals Co. Ltd., BioDiem Ltd, Biomics Biotechnologies Co., Ltd., Celgene Corporation, Cell Medica Limited , F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lakewood-Amedex Inc, Merck & Co., Inc., Merck KGaA, Molecular Partners AG, Novartis AG, Ono Pharmaceutical Co., Ltd., Pharmacyclics, Inc., Sapvax, Tessa Therapeutics Pte Ltd and Theravectys SA. Drug Profiles mentioned in this research report are abexinostat hydrochloride, Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer, apatinib, ARGX-110, atezolizumab, avelumab, azacitidine, baltaleucel-T, Cellular Immunotherapy for Multiple Sclerosis, Cellular Immunotherapy for Nasopharyngeal Cancer, Cellular Immunotherapy for Oncology, Cellular Immunotherapy for Oncology, Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders, Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology, Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma, DC-120, EBV-nRNA, Epstein-Barr virus vaccine, ficlatuzumab, GSK-2849330, icotinib hydrochloride, JS-001, LAG-525, Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma, Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma, MP-0250, MVA vaccine, NEO-212, nimotuzumab, nivolumab, PDR-001, pembrolizumab, RO-5203280, Small Molecules for asopharyngeal and Colon Cancers, SV-638, TT-10, Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma, Vaccine for Oncology and Vaccine to Target EBV for Nasopharyngeal Carcinoma.
Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=703639 .
Another newly published market research report titled Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H2 2016 provides comprehensive information on the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development are Acceleron Pharma, Inc., AstraZeneca Plc, AVEO Pharmaceuticals, Inc., Celgene Corporation, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., HanAll Biopharma Co., Ltd., Johnson & Johnson, Millennium Pharmaceuticals Inc, Mirna Therapeutics, Inc., Molecular Partners AG, MolMed S.p.A., Novartis AG, OncoMed Pharmaceuticals, Inc., Pfizer Inc., PharmAbcine, Inc. and Verlyx Pharma Inc. Metastatic Hepatocellular Carcinoma (HCC) Pipeline market research report of 131 pages is available at http://www.reportsnreports.com/reports/697563-metastatic-hepatocellular-carcinoma-hcc-pipeline-review-h2-2016.html .
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Maharashtra, India. Tel: +1-888-391-5441 firstname.lastname@example.org
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts